ロード中...
miR-130a can predict response to temozolomide in patients with glioblastoma multiforme, independently of O6-methylguanine-DNA methyltransferase
BACKGROUND: Currently, O6-methylguanine-DNA methyltransferase(MGMT) promoter methylation is the most convincing predictive biomarker for temozolomide (TMZ) response in patients with glioblastoma multiforme (GBM). However, technical obstacles prevent this biomarker from being applied widely. On the o...
保存先:
| 出版年: | J Transl Med |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4345002/ https://ncbi.nlm.nih.gov/pubmed/25890369 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-015-0435-y |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|